In comparison to other GRPR-targeting agents, [177Lu]Lu-NeoB favorably compares with GRPR-radioagonists [177Lu]Lu-AMBA and [177Lu]Lu-BBN8, which exhibited tumor-to-pancreas and tumor-to-gastro-intestinal tract ratio < 1 at 24 h p.i [35]. The gene discussed is GRPR; the disease is neoplasm.